OBJECTIVE To assess the prevalences of anemia and various RBC anomalies in dogs with lymphoma versus inflammatory bowel disease (IBD) and to evaluate potential relationships between these variables and the severity of lymphoma.
DESIGN Retrospective cross-sectional study.
ANIMALS 82 client-owned dogs.
PROCEDURES Medical records and blood smears were reviewed for dogs in which IBD or lymphoma had been diagnosed between January 1, 2006, and December 31, 2014, and for healthy dogs evaluated during that time frame. Hematologic data were analyzed, and results were compared among groups of healthy dogs, dogs with IBD, and dogs with lymphoma. Results were also compared within the lymphoma group between dogs further grouped on the basis of lymphoma clinical stage, substage, and cell size.
RESULTS Prevalence of anemia was significantly higher in dogs with lymphoma (17/32 [53%]) than in dogs with IBD (5/23 [22%]). The total number of different RBC anomalies was significantly higher in dogs with lymphoma than in dogs that were healthy or had IBD. A cutoff of 3 different RBC anomalies/dog enabled differentiation between lymphoma and IBD, with a sensitivity and specificity of 71% and 70%, respectively (area under the fitted curve, 0.7239 ± 0.0727). The presence of eccentrocytes was the only individual RBC anomaly significantly more common in dogs with lymphoma (8/28 [29%]) versus dogs with IBD (1/23 [4%]).
CONCLUSIONS AND CLINICAL RELEVANCE Results suggested that detection of anemia combined with ≥ 3 RBC morphological anomalies, particularly eccentrocytes, on blood smears should increase the clinical suspicion of lymphoma, compared with IBD, in dogs.
Objectives—To determine whether telomerase activity
was present in lymph nodes, buffy coat, and
serum samples from dogs with malignant lymphoma
(ML) and in liver, lymph node, buffy coat, and serum
samples from clinically normal dogs
Sample Population—Tissue specimens and blood
samples were obtained from 11 clinically normal adult
dogs (age range, 1 to 4 years) and 14 client-owned
dogs with ML.
Procedure—The telomere repeat amplification protocol
assay was used to quantify telomerase activity in the
tissues from clinically normal dogs and dogs with ML.
Results—Of 11 clinically normal dogs, 8 had lymph node
samples, 5 had liver samples, and 1 had buffy coat samples
with detectable telomerase activity. None of the
serum samples from the clinically normal dogs had
detectable telomerase activity. Of 14 dogs with ML, 9 had
lymph node samples, 3 had buffy coat samples, and 1 had
serum samples with measurable telomerase activity.
Conclusions and Clinical Relevance—Telomerase
activity was not specific to tumor cells and overlapped
with that found in cells from clinically normal dogs.
Telomerase activity in neoplastic lymph nodes was
not substantially different from that found in lymph
nodes from clinically normal dogs. The determination
of telomerase activity cannot be used as a sole diagnostic
test for cancer. Therapeutic modalities directed
toward the telomerase enzyme may not be feasible in
dogs, because somatic tissues from clinically normal
dogs possess variable amounts of telomerase activity.
(Am J Vet Res 2001;62:1442–1446)